Illumina (ILMN) Expected to Post Earnings on Thursday

Illumina (NASDAQ:ILMN) is anticipated to announce its Q2 2026 results after the market closes on Thursday, July 30th. Analysts expect Illumina to post earnings of $1.23 per share and revenue of $1.1306 billion for the quarter. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Parties can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, July 30, 2026 at 4:30 PM ET.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, topping the consensus estimate of $1.05 by $0.10. The business had revenue of $1.09 billion during the quarter, compared to analysts’ expectations of $1.07 billion. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The firm’s revenue was up 4.8% on a year-over-year basis. During the same period in the previous year, the business earned $0.97 earnings per share. On average, analysts expect Illumina to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Illumina Stock Performance

Shares of ILMN opened at $189.47 on Tuesday. Illumina has a 12-month low of $88.00 and a 12-month high of $199.14. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56. The company has a market cap of $28.67 billion, a PE ratio of 34.45, a price-to-earnings-growth ratio of 2.87 and a beta of 1.47. The stock has a 50-day moving average price of $172.20 and a 200-day moving average price of $145.73.

Analyst Ratings Changes

ILMN has been the subject of a number of research reports. Guggenheim boosted their price target on shares of Illumina from $180.00 to $200.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Citigroup upped their target price on shares of Illumina from $80.00 to $95.00 and gave the stock a “sell” rating in a research report on Monday, May 4th. Leerink Partners increased their target price on Illumina from $175.00 to $210.00 and gave the company an “outperform” rating in a research note on Friday, July 17th. TD Cowen restated a “hold” rating on shares of Illumina in a research report on Wednesday, July 15th. Finally, Piper Sandler increased their price objective on Illumina from $170.00 to $200.00 and gave the company an “overweight” rating in a research report on Wednesday, July 1st. Nine analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $156.88.

Insider Buying and Selling at Illumina

In related news, SVP Patricia Leckman sold 783 shares of the stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $162.59, for a total transaction of $127,307.97. Following the completion of the sale, the senior vice president directly owned 21,259 shares in the company, valued at $3,456,500.81. This represents a 3.55% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 235,000 shares of Illumina stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $163.63, for a total value of $38,453,050.00. Following the completion of the transaction, the director directly owned 2,830,452 shares in the company, valued at $463,146,860.76. This trade represents a 7.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 1,003,769 shares of company stock valued at $155,710,908. Corporate insiders own 2.90% of the company’s stock.

Institutional Investors Weigh In On Illumina

A number of large investors have recently added to or reduced their stakes in ILMN. Quarry LP bought a new stake in shares of Illumina in the 3rd quarter worth approximately $32,000. Brown Brothers Harriman & Co. lifted its stake in Illumina by 975.6% in the fourth quarter. Brown Brothers Harriman & Co. now owns 441 shares of the life sciences company’s stock worth $58,000 after acquiring an additional 400 shares during the period. Itau Unibanco Holding S.A. boosted its holdings in Illumina by 93.1% in the fourth quarter. Itau Unibanco Holding S.A. now owns 556 shares of the life sciences company’s stock valued at $73,000 after acquiring an additional 268 shares in the last quarter. Advisory Services Network LLC purchased a new position in Illumina during the 3rd quarter valued at $102,000. Finally, Smartleaf Asset Management LLC increased its position in Illumina by 16.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,329 shares of the life sciences company’s stock valued at $176,000 after purchasing an additional 186 shares during the period. Institutional investors own 89.42% of the company’s stock.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.